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ABSTRACT We have developed an immunotherapy in
which tumor cells transfected with syngeneic major histocom-
patibility complex (MHC) class II genes are cell-based vac-
cines for the treatment of established tumor and metastatic
disease. If this strategy is to be used clinically, convenient
methods for generating class II1 tumor cells are necessary.
Interferon-g treatment or transduction of the class II trans-
activator (CIITA) gene induces class II expression but also
up-regulates the class II-associated accessory molecules, in-
variant chain (Ii) and DM. To determine if interferon-g
treatment and CIITA transduction are potential immunother-
apies, we assessed the tumorigenicity of sarcoma cells express-
ing combinations of class II, Ii, and DM. Since we hypothe-
sized that class II-transfected tumor cells not coexpressing Ii
and DM present endogenously encoded tumor peptides, we
have assessed the transfectants for antigen presentation ac-
tivity to MHC class II-restricted antigen-specific CD41 T
cells. Tumor challenge studies demonstrate that tumor cells
expressing class II without coexpression of Ii or Ii plus DM are
highly immunogenic and preferentially present endogenous
antigens, while tumors coexpressing class II with Ii or Ii plus
DM are not effective immunogens. Because tumor rejection
correlates with expression of class II without coexpression of
Ii and DM, the most efficacious vaccines will express MHC
class II without coexpression of Ii and DM and will prefer-
entially present endogenous antigen.
Numerous strategies for enhancing the immune response to
autologous tumors have recently been developed. Many of the
approaches directly target the activation of tumor-specific
CD81 effector T lymphocytes, since these cells are efficient
mediators of tumor-specific immunity (1). In contrast, we (2,
3) and others (4–6) have reasoned that improved generation
of tumor-specific CD41 T helper cells enables tumor-specific
CD81 T cells to function more efficiently and, therefore, have
focused on activating CD41 T cells. We have used gene
transfection to express syngeneic major histocompatibility
complex (MHC) class II genes in tumor cells so that the tumor
cells can directly present tumor peptides to CD41 T helper
lymphocytes and bypass the need for host antigen-presenting
cells (APC) and soluble tumor antigen. Immunization of
autologous mice with class II-transfected tumor cells protects
against subsequent challenges of wild-type (class II2) primary
tumor in a sarcoma model (2), decreases metastatic disease in
two melanoma models (7), and mediates regression of a
wild-type, long-term established, solid tumor in a sarcoma
model (8). T cell depletion experiments established that class
II-transfected tumor cells stimulate tumor-specific CD41 T
cells because they are more immunogenic than wild-type class
II2 tumor cells (2, 8). Immunization with class II-transfected
tumor cells, therefore, induces a potent tumor-specific immu-
nity that could be exploited for immunotherapy.
To develop the CD41 T cell activation strategy and methods
for predicting its potential clinical application, we are explor-
ing additional approaches to enhance MHC class II expression.
The two most practical of these approaches, interferon g
(IFN-g) treatment (9) and class II transactivator (CIITA) gene
transduction (10), not only increase autologous MHC class II
expression but also up-regulate class II-associated accessory
molecules, such as invariant (Ii) chain and DM (11–13). If
IFN-g treatment andyor CIITA gene expression are to be
considered as immunotherapeutic strategies for treating tu-
mor-bearing patients, the effects of class II-associated acces-
sory molecule expression on class II-transfected tumor cell
immunogenicity should be determined. We have, therefore,
generated and determined the tumorigenicity of various sar-
coma transfectants expressing different combinations of syn-
geneic MHC class II, Ii, and DM. Since we originally hypoth-
esized that class II-transfected tumor cells that do not coex-
press class II accessory molecules will present endogenously
synthesized tumor peptides (2, 3), we have also assessed the
ability of the various transfectants and transductants to present
MHC class II-restricted antigen to antigen-specific CD41 T
cells. Our results demonstrate that tumor cells expressing
syngeneic MHC class II without coexpression of Ii and DM are
the only transfectantsytransductants that induce tumor-
specific immunity and efficiently present class II-restricted,
endogenously synthesized antigens. Tumor cell coexpression
of Ii and DM along with class II, therefore, abrogates the
protective effects of class II expression, probably by preventing
tumor cells from presenting endogenously synthesized tumor
antigen(s). If cell-based vaccines using class II-transfected
tumor cells are to be used as immunotherapeutic agents to
generate tumor-specific CD41 T cells, then the most effective
vaccines will express MHC class II molecules and will not
coexpress Ii and DM molecules.
EXPERIMENTAL PROCEDURES
Mice and Tumor Challenges. All mice were purchased from
The Jackson Laboratory andyor bred in the University of
Maryland Baltimore County animal facility. For tumor chal-
lenges, mice were inoculated intraperitoneally (i.p.) with 106
tumor cells. This dose was chosen on the basis of previous in
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vivo tumor cell titrations (2, 14). After tumor challenge, mice
were checked for tumor incidence 2–3 times per week, and
sacrificed when moribund. Tumor-challenged mice were ob-
served for up to 3 months and were considered tumor-free if
they did not develop a palpable tumor during the observation
period. Tumor incidence is the number of mice with tumor
divided by the total number of mice injected.
Cell Lines. SaI, SaIyAk, and SaIyAkyIi transfectants were
generated as described (2, 15). All tumor cells, transfectants,
and transductants were maintained in Iscove’s modified Dul-
becco’s medium (IMDM) supplemented with 5% Fetalclone I
(HyClone), 1% penicillin, and 1% streptomycin. Additionally,
SaIyAk, SaIyAkyIi, and SaIyCIITA transfectants were main-
tained in 400 mgyml G418, and lysozyme transfectants, in 400
mgyml hygromycin. Cells transfected with both pSV2neo and
pSV2hph plasmids were maintained in G418 and hygromycin.
SaIyAkyIi cells were periodically enriched for class II expres-
sion by magnetic bead separation (Dynal).
Plasmids and Retrovirus Preparation. Plasmid pKLK con-
tains a viral promoter driving the hen eggwhite lysozyme
(HEL) gene linked to the MHC class I transmembrane region
of H-2Kb (16). This construct was used to generate SaI
sarcoma cells expressing a membrane-bound HEL (mHEL).
Plasmid pHYK contains a viral promoter driving the HEL
gene fused to a KDEL endoplasmic reticulum (ER) retention
signal (erHEL) (17). These plasmids were the generous gifts of
C. Goodnow and H. Pelham, respectively. Plasmid pSV2hph
contains the hygromycin phosphotransferase gene (14). The
extrachromosomal expression vector BCMGhph (18) was
kindly provided by D. Pardoll. Plasmid BCMGhph-erHEL was
generated by subcloning a blunt-ended HindIIIyBamHI frag-
ment containing the HEL gene from the pHYK plasmid into
the unique XhoI site of the BCMGhph vector.
For the CIITA construct, the EcoRIyEcoRI fragment of the
pcDNA3.FLAG.CIITA construct (58) was cloned into the
EcoRI site of the LXSNb retroviral plasmid, and production
of retrovirus was as described (19).
Transfectants and Transductants. Transfections were per-
formed as previously described (15) using 25–50 ml of Lipo-
fectin (GIBCO) and 0.2–1 mg of pSV2hph plus 10–30 mg of
pKLK per 106 cells in 3 ml for mHEL or 10 mg of BCMGhph-
erHEL per 106 cells in 3 ml for erHEL transfectants. Trans-
fectants were selected using 400 mgyml hygromycin (Calbio-
chem). mHEL transfectants were cloned by limiting dilution.
For retroviral infection, 105 SaI cells in mid-logarithmic
growth phase were incubated for 2 hr with 250 ml of viral
supernatant containing 8 mgyml Polybrene. After incubation,
the viral supernatant was replaced with fresh growth medium.
Two days later the cells were passaged 1:20 and placed in
selection (400 mgyml G418). The polyclonal population was
then analyzed for class II expression and cloned by limiting
dilution.
Antigen-Presentation Assays. Antigen-presentation assays
were performed in 96-well f lat-bottomed plates in a total
volume of 300 ml per well of IMDM supplemented with 10%
heat-inactivated Fetalclone I, 1% penicillin, and 1% strepto-
mycin. HEL-(46–61)-specific, I-Ak-restricted 3A9 hybridoma
cells (20) were irradiated with 2,200 rads (1 rad 5 0.01 Gy) and
mixed (5 3 104 per well) with SaI-derived APC (23,000 rads)
or irradiated (2,400 rads) TA3 control B lymphoma cells (21).
In initial experiments, ratios of 1:1, 2:1, and 5:1 3A9:APC were
used. A ratio of 1:1 3A9:APC was used in subsequent exper-
iments because it consistently gave the highest stimulation
values. Cells were incubated at 37°C for 24 hr, and 50-ml
samples of the supernatants were either frozen or assayed
immediately for interleukin 2 (IL-2). IL-2 was measured by
ELISA using an Endogen (Cambridge, MA) IL-2 kit and
following the instructions of the supplier. For exogenous
antigen presentation, intact or trypsin-digested HEL (22) was
added to each well to a final concentration of 1 mgyml. All
wells were prepared in triplicate, and the average and standard
deviation for each experimental condition were determined.
Standard deviations usually did not exceed 5–10%.
Antibodies. Hybridoma cell lines secreting the lysozyme-
specific mAbs HyHEL 7 and HyHEL 10 (23) were kindly
supplied by S. Smith-Gill and were affinity purified on protein
G as described (2). The MHC class I (11–4.1: H-2Kk-specific)
and invariant chain (In-1) mAbs have been described (2, 15).
10–2-16 is an MHC class II I-Ak-specific mAb (24). The
polyclonal rabbit antiserum K553 against mouse DM (H-2M)
was kindly supplied by L. Karlsson (25).
Immunofluorescence. Live cells were stained by indirect
immunofluorescence for cell surface markers (MHC class II,
class I, mHEL) as described (2), using the 10–2-16, 11–4-1, or
a cocktail of HyHEL 7 plus HyHEL 10 mAbs. Cells stained for
internal markers (Ii, erHEL, DM) were fixed in 1% or 2%
paraformaldehyde, permeabilized with 0.2% saponin, and
then stained as for live cells (2) except 0.2% saponin was
included in the wash medium and in all diluted reagents.
erHEL transfectants were stained with a cocktail of HyHEL 7
plus 10 mAbs followed by a goat anti-mouse IgG-fluorescein
isothiocyanate (FITC) conjugate (Cappel). Ii transfectants
were stained with the In-1 mAb followed by an F(ab9)2 goat
anti-rat IgG-FITC conjugate (Cappel). CIITA transductants
were stained with the polyclonal rabbit anti-DM (no. K553)
antiserum followed by an F(ab9)2 goat anti-rabbit IgG-FITC
(Cappel). Cells were analyzed on a Coulter XL flow cytometer.
RESULTS
Sarcoma Tumor Cells Transfected with Syngeneic MHC
Class II Genes Are Rejected by Autologous or Semisyngeneic
Mice, While Sarcoma Cells Expressing Class II plus Ii Chain,
With or Without DM, Are Highly Malignant. Tumor expres-
sion of autologous MHC class II molecules can be increased by
several methods, including transfection or transduction of class
II genes (2), incubation of tumor cells with IFN-g (9), or
expression of the CIITA gene (10, 12, 26–29). Although the
latter two approaches induce MHC class II expression, they
also induce expression of the class II-associated accessory
molecules Ii and DM. To determine if coexpression of Ii and
DM with class II affects the therapeutic value of class II-
transfected tumor cells, we have generated transfectantsy
transductants expressing class II genes and various combina-
tions of Ii and DM and have tested their immunogenicity.
Fig. 1 shows flow cytometry profiles of wild-type SaI sar-
coma cells, SaI cells expressing syngeneic MHC class II Aak
and Abk genes (SaIyAk tumor cells), SaIyAk cells expressing Ii
(SaIyAkyIi tumor cells), and SaI cells transduced with the
CIITA gene (SaIyCIITA tumor cells). Tumor cells were
stained by indirect immunofluorescence for syngeneic MHC
class II molecules (I-Ak), Ii, or DM. Cell-surface MHC class II
expression was assessed on live cells, while internal Ii and DM
expression was assessed in fixed cells. As shown in Fig. 1 A,
wild-type SaI cells do not express I-Ak, Ii, or DM (panels a, o,
or u, respectively), while SaIyAk cells express I-Ak but not Ii or
DM (panels d, r, and v, respectively). As shown in Fig. 1B, three
clones of SaIyAkyIi cells (clones 6, 7, and 9) express I-Ak
(panels a, c, and e) and intracellular Ii (panels p, r, and t) but
not DM (panels w, x, and y). SaIyCIITA cells express I-Ak, Ii,
and DM (Fig. 1C, panels d, t, and y), while vector-alone-
transduced SaI cells (SaIyLXSN) do not express class II, Ii, or
DM (Fig. 1C panels a, q, and x.) MHC class I levels on these
cells are comparable to class I levels on SaI sarcoma cells (data
not shown, but see refs. 2 and 15).
In previous studies, immunotherapeutic potential of SaI
transfectants correlated with their tumorigenicity (2, 8, 15, 30).
To test the immunogenicity of the transfectants and transduc-
tants, mice were challenged i.p. with tumor cells and moni-
tored for ascites tumor growth and survival. Both autologous




















(AyJ) and semisyngeneic [(C57BLy6 3 AyJ)F1] mice were
used because previous experiments have established that SaI
tumor growth is the same in both strains (ref. 31 and T.D.A.,
unpublished results). As shown in Table 1, wild-type class II2
SaI, SaIyAkyIi, and SaIyCIITA tumor cells are highly tumor-
igenic. SaIyAkyIi lines have been tested for tumorigenicity in
AyJ mice, and they were found to form tumors in 50–100% of
tested animals (15). SaIyAk tumor cells, however, are uni-
formly rejected. These results agree with earlier findings that
class II-transfected tumor cells are highly immunogenic in
autologous hosts, while tumor cells coexpressing Ii are lethal.
Optimal immunogenicity and tumor rejection, therefore, occur
when sarcoma cells express syngeneic MHC class II molecules
and do not coexpress class II-associated accessory molecules.
SaI Tumor Cells Transfected with the HEL Gene Express
Lysozyme in the Appropriate Targeted Cellular Compart-
ment. We originally hypothesized that class II-transfected
tumor cells that do not coexpress Ii andyor DM would present
endogenously synthesized tumor peptides and be effective
APC that activate CD41 Th (helper) lymphocytes (2, 3). Such
tumor cells should be significantly more immunogenic than
wild-type class II2 tumor cells. To determine if this hypothesis
explains the differential tumorigenicity of the SaI, SaIyAk,
SaIyAkyIi, and SaIyCIITA tumors, we have assessed their
relative ability to present MHC class II-restricted antigen to
CD41 T cells. Since our hypothesis is that class II-transfected
tumor cells would be more efficient presenters of any class
II-restricted endogenous antigen, SaI sarcoma cells were trans-
fected with the HEL gene, and presentation of lysozyme as an
endogenous antigen has been assessed. HEL serves as a
convenient model antigen in these studies for two reasons:
I-Ak-restricted hybridomas (20) and cloned lysozyme genes
(17, 16) are available for measuring HEL presentation. Fur-
thermore, sarcoma transfectants expressing HEL in the ER
(erHEL) or plasma membrane (mHEL) have been generated,
thereby mimicking some of the intracellular locations in which
tumor antigens are localized.
As shown in Fig. 1, SaI, SaIyAk, SaIyAkyIi, and SaIyCIITA
tumor cells transfected with the erHEL plasmid (SaIyerHEL,
SaIyAkyerHEL, SaIyAkyIiyerHEL, and SaIyCIITAyerHEL
cells, respectively), or the mHEL plasmid (SaIymHEL, SaIy
AkymHEL, SaIyAkyIiymHEL, and SaIyCIITAymHEL cells,
respectively) express lysozyme in the ER or at the plasma
membrane (Fig. 1 A, panels g–n; Fig. 1B, panels h–o; and Fig.
Table 1. Sarcoma cells expressing syngeneic MHC class II
molecules are rejected, while sarcoma cells coexpressing class II




AyJ (C57BLy6 3 AyJ)F1
SaI 106 2y2 10y10
SaIyAk 106 0y5 0y5
SaIyAkyIi-6 106 NT 4y5
SaIyAkyIi-7 106 NT 8y9
SaIyAkyIi-9 106 NT 8y10
SaIyLXSN 106 5y5 5y5
5 3 105 3y5
105 1y5
SaIyCIITA 106 5y5 5y5
5 3 105 4y5
105 5y5
The indicated number of sarcoma cells were inoculated i.p. into
autologous AyJ or semisyngeneic (C57BLy6 3 AyJ)F1 mice, and the
mice were followed for tumor incidence. NT, not tested. Institutional
Animal Care and Use Committee guidelines mandate that moribund
animals be sacrificed to minimize pain and discomfort. On the basis of
previous studies, mean survival times of these mice would have been
14–19 days.
FIG. 1. Expression of MHC class II, Ii, and HEL in SaI and
SaI-transfected tumor cells. (A) SaI and SaIyAk sarcoma cells and
their transfectants were stained for MHC class II (a–f), ER-retained
HEL (g–j), plasma membrane HEL (k–n), Ii (o–t), or DM (u and v).
(B) Three SaIyAkyIi transfected sarcoma lines (Ii-6, Ii-7, Ii-9) were
stained for MHC class II (a–g), ER-retained HEL (h–k), plasma
membrane HEL (l–o), Ii (p–v), or DM (w–y). (C) SaIyLXSN or
SaIyCIITA sarcoma cells and their transfectants were stained for
MHC class II (a–g), ER-retained HEL (h–k), plasma membrane HEL
(l–p), Ii (q–w), or DM (x and y). In all panels, broken lines represent
specific antibody staining; solid lines represent secondary fluorescent
conjugate staining without primary antibody. MHC class II (10–2.16
mAb) and plasma membrane HEL (HyHEL 7, HyHEL 10 mAbs)
staining was performed on live cells; internal HEL (ER-retained) and
Ii chain staining was performed on fixed cells.




















1C panels h–p). MHC class II (I-Ak), Ii, and DM expression in
the transfectants is comparable to expression in the non-
lysozyme-transfected tumors (Fig. 1). Cell lines transfected
with vector alone show class II, Ii, and HEL levels comparable
to untransfected parental cells (Fig. 1 C and data not shown).
MHC class I antigen expression in lysozyme transfectants is
comparable to expression in untransfected cells (data not
shown). Transfection of these tumor cells with the HEL gene,
therefore, yields tumor cells that express lysozyme in the
appropriate cellular compartment, and maintain MHC class II,
class I, Ii, andyor DM expression comparable to their non-
lysozyme-transfected relatives.
Class II-Transfected Tumor Cells Present ER-Retained
Endogenously Synthesized HEL Provided They Do Not Coex-
press Ii. To determine if class II-transfected sarcoma cells
present endogenously synthesized antigens, SaI yAkyerHEL
tumor cells were co-cultured with the I-A k-restricted lysozyme-
specific 3A9 hybridoma, and IL-2 secretion was measured. As
shown in Table 2, SaIyAkyerHEL cells stimulate IL-2 produc-
tion, while control SaIyerHEL cells do not. SaIyAk cells,
therefore, express a functional MHC class II molecule, and
present ER-retained endogenously synthesized antigen. To
determine if Ii and DM coexpression affect presentation of
ER-retained lysozyme, two SaI yAkyIiyerHEL clones and SaIy
CIITAyerHEL cells were also tested as APC. As shown in
Table 2, neither SaIyAkyIiyerHEL nor SaIyCIITAyerHEL
cells cause IL-2 release. Class II 1 tumor cells, therefore,
present ER-retained antigen; however, coexpression of Ii or Ii
plus DM prevents presentation.
Class II-Transfected and CIITA-Transduced, but Not Ii-
Transfected, Tumor Cells Present Membrane-Associated
HEL. To determine if class II-transfected sarcoma cells
present endogenously synthesized antigen targeted to the
plasma membrane, SaIymHEL, SaIyAkymHEL, SaIyAkyIiy
mHEL, and SaIyCIITA tumor cells were tested as APC to
3A9. As shown in Table 3, SaIyAkymHEL cells induce IL-2
synthesis, while control SaIymHEL cells do not. Two clones of
SaIyAkyIiymHEL cells also do not stimulate IL-2 release,
while SaIyCIITAymHEL cells do. Class II-transfected sar-
coma cells, therefore, present endogenously synthesized anti-
gen targeted to the plasma membrane if class II is expressed
alone, or coexpressed with Ii and DM; however, tumor cells
expressing class II and Ii without DM do not present mem-
brane-targeted antigen.
Sarcoma Tumor Cells Do Not Present Exogenous Intact
Lysozyme Unless They Are Transduced with the CIITA Gene.
We originally hypothesized that class II-transfected sarcoma
cells are more immunogenic because they preferentially
present endogenously synthesized tumor antigens. An alter-
native explanation for their increased immunogenicity is that
they are efficient processors and presenters of exogenously
synthesized antigen. To distinguish these two possibilities, SaI
or SaIyAk sarcoma cells were incubated with 3A9 hybridoma
cells in the presence of exogenous intact HEL. TA3 cells, which
are professional APC, were included as a reference standard.
As shown in Table 4, neither SaI nor SaIyAk cells stimulate
IL-2 release, while TA3 cells consistently stimulate high levels
of IL-2 release. Class II-transfected sarcoma cells are, there-
fore, unable to process andyor present exogenous intact antigen.
Since numerous studies have demonstrated that Ii and DM
expression can have profound effects on presentation of
exogenous antigen by class II1 APC (32, 33), we assessed
presentation of exogenous antigen by sarcoma cells coexpress-
ing class II, Ii, and Ii plus DM. SaIyAkyIi and SaIyCIITA cells
were incubated with 3A9 hybridoma cells in the presence of
exogenous intact HEL, and IL-2 production was measured. As
shown in Table 4, three independent SaIyAkyIi clones and
control SaIyLXSN sarcoma cells are unable to present exog-
enous HEL, while SaIyCIITA sarcoma cells present exogenous
antigen, although the presentation is less efficient than by the
professional APC, TA3. The ability to present exogenous
intact antigen, is, therefore, limited to sarcoma cells that
express class II, Ii, and DM.
Class II-Transfected Tumor Cells Present Low Levels of
Exogenously Synthesized HEL Peptide. As shown in Table 4,
class II-transfected tumor cells do not present exogenously
synthesized antigen unless they coexpress Ii and DM. Lack of
presentation may be due to the cells’ inability to internalize and
process antigen or to their inability to bind and present
peptide. If class II-transfected tumor cells are unable to
internalize and process exogenous antigen but are able to bind
and present peptide, then transfectants given peptide antigen
should activate antigen-specific hybridomas. To distinguish
these possibilities, class II-transfected tumor cells were pulsed
with trypsin-digested HEL in the presence of 3A9 hybridoma
cells, and IL-2 production was measured. As shown in Table 5,
SaIyAk cells present lysozyme peptide better than they present
intact lysozyme (compare with Table 4), but not as efficiently
as the professional APC line, TA3. Since studies by other
Table 2. SaIyAk, but not SaIyAkyIi or SaIyCIITA, tumor cells





Exp. 1 Exp. 2 Exp. 3 Exp. 4 Exp. 5 Exp. 6
SaI or SaIyLXSN 0 0 0
SaIyAk 79.2 47.5 85.8 594 198 99
SaIyAkyIi-7 0 0 9.9
SaIyAkyIi-9 0 0 0
SaIyCIITA 0 0 0
APC are transfectants expressing approximately equivalent levels of
erHEL (see flow cytometry profiles in Fig. 1). APC were cocultured
with 3A9 hybridoma cells, and IL-2 release was measured by ELISA.
Six independent experiments are shown.




Exp. 1 Exp. 2 Exp. 3
SaI 0 0 0
SaIyAk 0 0 52.8
SaIyAkyIi-6 17.2
SaIyAkyIi-7 14.5 0 0
SaIyAkyIl-9 0 0 0
SaIyLXSN 15
SaIyCIITA 376 171.6
TA3 3,696 .1,386 .3,234
APC were incubated with intact soluble HEL and 3A9 hybridoma
cells, and IL-2 production was measured by ELISA. Three indepen-
dent experiments are shown.
Table 3. SaIyAk and SaIyCIITA, but not SaIyAkyIi, cells





Exp. 1 Exp. 2 Exp. 3 Exp. 4 Exp. 5 Exp. 6
SaI or SaIyLXSN 0 0 0
SaIyAk 151.8 330 316.8 405 514.8 138.6
SaIyAkyIi-6 6.6 0 0
SaIyAkyIi-9 0 0 0
SaIyCIITA 8.27 990 .1,749
SaIyCIITA 15.11 1,056 798.6
All APC are transfectants expressing approximately equal quanti-
ties of mHEL (see Fig. 1 for flow cytometry quantitation). APC were
incubated with HEL-specific 3A9 T cell hybridoma cells, and IL-2
release was measured by ELISA. Six independent experiments are
shown.




















investigators have demonstrated that coexpression of Ii and
DM significantly affects presentation of exogenous antigen
(25, 34), we have also assessed SaIyAkyIi and SaIyCIITA as
APC for exogenous lysozyme peptide. As shown in Table 5,
one of the SaIyAkyIi lines does not present exogenous peptide,
while the second SaIyAkyIi line and SaIyCIITA cells minimally
present exogenous peptides. Class II-transfected sarcoma cells,
therefore, are inefficient presenters of exogenous peptide
relative to professional APC, and coexpression of Ii or Ii plus
DM reduces presentation efficiency further.
DISCUSSION
Immunization of tumor-bearing mice with syngeneic MHC
class II-transfected autologous tumor cells yields significant
regression of established primary sarcoma tumors (8). If this
approach is to be used clinically, it will be necessary to develop
convenient methods for generating class II1 tumor cells. The
two most practical methods, treatment with IFN-g (9) and
transfectionytransduction of the CIITA gene (10), also up-
regulate the class II-associated accessory molecules, Ii and DM
(11–13), but our results demonstrate that tumor cells coex-
pressing class II with Ii, or Ii plus DM are not effective
immunogens against tumor. IFN-g or CIITA gene expression
is, therefore, unlikely to be useful clinically. Furthermore, if
cell-based vaccines aimed at stimulating tumor-specific CD41
Th cells are to be adapted clinically, they should contain MHC
class II molecules, and not coexpress Ii and DM.
Some human tumors either constitutively express MHC class
II or are inducible for class II expression by IFN-g (e.g.,
melanoma and mammary carcinoma). However, tumor cell
class II expression does not always correlate with disease
prognosis (35, 36). Since constitutively class II1 tumor cells and
IFN-g-treated tumor cells coexpress Ii and DM, these cells are
probably not any more efficient at inducing a tumor-specific
CD41 T cell response than class II2 tumor cells. Hence, in situ
class II expression by tumor cells is unlikely to be a prognostic
indicator for tumor regression.
Although the immunotherapeutic effect of class II-
transfected sarcoma cells has been demonstrated (8, 14, 37),
the mechanism of action has not been characterized. We
originally hypothesized that class II1 Ii2 tumor cell transfec-
tants present endogenously encoded tumor antigen(s) in the
context of self MHC class II to CD41 T cells (3, 15, 37). This
hypothesis is consistent with numerous published studies on
the mechanism of class II-mediated antigen presentation,
including (i) experiments showing that class II molecules
present endogenously synthesized peptides (38–42), although
they usually present exogenously synthesized antigens (43); (ii)
demonstration that the MHC class II heterodimer binds
endogenously synthesized antigen in the ER, provided Ii chain
is not present (44); and (iii) sequence analysis studies demon-
strating that endogenous peptides are bound to cell surface
MHC class II dimers (45). Our studies are consistent with this
hypothesis, since they demonstrate that class II-transfected
sarcoma cells present class II-restricted endogenously encoded
antigen.
An alternative mechanism for the increased immunogenic-
ity of class II-transfected tumor cells is that they endocytose
exogenous antigen and re-present it. Three observations argue
against this mechanism: (i) Class II-transfected tumor cells do
not present exogenous intact antigen (Table 4). (ii) Class
II-transfected tumor cells are inefficient presenters of exoge-
nous peptide (Table 5). (iii) SaIyCIITA tumor cells, which
present exogenous intact antigen, are tumorigenic (Table 1).
Therefore, presentation of exogenous antigen does not corre-
late with tumor cell immunogenicity, and re-presentation of
exogenous antigen is unlikely to contribute to tumor rejection.
Taken together, these data suggest that the most likely mech-
anism for enhanced immunogenicity of class II-transfected
sarcoma cells is their ability to activate CD41 T cells by means
of cell surface expression of MHC class IIytumor peptide
complexes.
Several studies suggest that coexpression of Ii is required for
expression of functional MHC class II molecules (46–48).
Other studies, however, including those reported here (Tables
2, 3, and 5), demonstrate that class II molecules are functional
in the absence of Ii (39, 40, 44). Other studies suggest that I-Ak
and I-Ek are less dependent on Ii coexpression for functional
integrity (49). In addition to the tumors reported here, we have
also transfected H-2b and H-2d tumors (melanoma B16 and
mammary carcinoma 4T1, respectively) with syngeneic MHC
class II genes and shown that these tumors stimulate tumor
immunity (ref. 7; B. A. Pulaski and S.O.-R., unpublished
results). Other investigators have transfected I-Ak or I-Ek class
II genes into other tumors and shown functional expression of
class II molecules in the absence of Ii (4, 50). Therefore, for at
least three MHC haplotypes and five different tumors, trans-
fection of MHC class II genes results in expression of func-
tional class II molecules.
The immunotherapeutic strategy described here uses autol-
ogous tumor cells as the immunogen. Not all human malig-
nancies will be amenable to this approach, since not all cancers
can be cultured or transduced in vitro. However, phase IyII
clinical trials using autologous tumor cells as immunothera-
peutic agents are currently underway for a variety of human
tumors [neuroblastoma, breast, melanoma, prostate, glioma,
papilloma (http://cancernet.nci.nih.gov)]. Although the focus
of our studies has been immunization with gene-modified
tumor cells, we have also defined some of the molecules that
facilitate T cell activation. By understanding which molecules
effectively induce tumor immunity, one may be able to design
more effective vaccines. Several scenarios may be possible if ex
vivo autologous tumor cells are not available. Genes encoding
known antigen-presentation molecules (i.e., MHC class II, B7,
etc.) could be introduced in situ by viral transduction (51) or
liposomes (52). Alternatively, autologous nontumor cells that
are more easily manipulated in vitro (e.g., fibroblasts), trans-
duced with the requisite antigen-presentation molecules and
tumor antigen genes, could be used as vaccines. Since new
tumor antigens are routinely being identified and character-
ized (53–55), and fibroblasts have been shown to be effective
delivery vehicles (56, 57), this approach is theoretically feasi-
ble. Noncellular delivery methods, such as liposomes recon-
stituted ex vivo with the relevant tumor antigen peptides plus
antigen-presentation molecules, could also be used. Regard-
less of the delivery approach, successful immunotherapy will
require a full understanding of antigen-presentation molecules
and tumor peptides that yield optimal T cell activation.
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Table 5. Exogenous HEL peptides are presented most efficiently




Exp. 1 Exp. 2 Exp. 3
SaI or SaIyLXSN 0 0 0
SaIyAk 39.6 211.2 151.8
SaIyAkyIi-7 19.8 112.2 39.6
SaIyAkyIi-9 0 0 33
SaIyCIITA 59.4 6.6 19.8
TA3 .1,333 .1,472 .2,746
APC, HEL, and 3A9 T cell hybridomas were incubated with
trypsin-digested HEL. IL-2 release was measured by ELISA. Three
independent experiments are shown.
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